Format

Send to

Choose Destination
JMIR Res Protoc. 2017 Oct 11;6(10):e195. doi: 10.2196/resprot.7750.

Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.

Author information

1
Eli Lilly and Company, Indianapolis, IN, United States.
2
HealthCore, Inc, Wilmington, DE, United States.

Abstract

BACKGROUND:

Survival outcomes are related to treatment choices in a line of therapy and to treatment sequences across all lines of therapy.

OBJECTIVE:

The Real-World Treatment Sequences and Outcomes among Patients with NSCLC (RESOUNDS) study is designed to (1) evaluate treatment sequences used for patients who receive at least two lines of therapy for non-small cell lung cancer (NSCLC) in the United States and (2) evaluate patient outcomes in terms of progression-free and overall survival related to treatment sequencing. Additional objectives include the evaluation of symptoms, comorbidities, and health care resource utilization and costs.

METHODS:

Patients will be censored at loss to follow-up due to leaving the health plan or reaching the end of the study period.

RESULTS:

This study is ongoing.

CONCLUSIONS:

The RESOUNDS cohort study is a novel approach to building a comprehensive dataset that mimics a prospective observational study using linked patient-level data from four real-world data sources. This study will provide timely information on the sequencing of treatments for patients with NSCLC.

KEYWORDS:

cancer; chemotherapy; line of therapy; non-small cell lung cancer; overall survival; progression-free survival; real-world data; regimen; treatment sequence

Supplemental Content

Full text links

Icon for JMIR Publications Icon for PubMed Central
Loading ...
Support Center